Phathom Pharmaceuticals (NASDAQ:PHAT) Raised to Hold at Wall Street Zen

Phathom Pharmaceuticals (NASDAQ:PHAT) was upgraded by equities researchers at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued to investors on Saturday.

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Phathom Pharmaceuticals in a report on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $17.50.

Phathom Pharmaceuticals Stock Performance

Shares of PHAT stock opened at $12.96 on Friday. The company has a market capitalization of $919.38 million, a PE ratio of -2.74 and a beta of 0.43. Phathom Pharmaceuticals has a 52-week low of $2.21 and a 52-week high of $19.50. The business’s fifty day moving average is $11.70 and its 200 day moving average is $8.35.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Jacobs Levy Equity Management Inc. bought a new stake in Phathom Pharmaceuticals during the first quarter worth about $3,738,000. GAMMA Investing LLC increased its position in shares of Phathom Pharmaceuticals by 797.2% during the 1st quarter. GAMMA Investing LLC now owns 4,558 shares of the company’s stock valued at $29,000 after purchasing an additional 4,050 shares during the last quarter. Russell Investments Group Ltd. purchased a new position in shares of Phathom Pharmaceuticals during the 1st quarter valued at about $262,000. US Bancorp DE raised its holdings in shares of Phathom Pharmaceuticals by 248.1% during the 1st quarter. US Bancorp DE now owns 23,763 shares of the company’s stock valued at $149,000 after buying an additional 16,937 shares in the last quarter. Finally, Wellington Management Group LLP lifted its position in Phathom Pharmaceuticals by 47.6% in the 1st quarter. Wellington Management Group LLP now owns 200,690 shares of the company’s stock worth $1,258,000 after buying an additional 64,695 shares during the last quarter. Institutional investors own 99.01% of the company’s stock.

Phathom Pharmaceuticals Company Profile

Phathom Pharmaceuticals, Inc, biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach.